Major Depressive Disorder - Pipeline Insight, 2021
![](/report_cover/8047/major-depressive-disorder-pipeline-insight-2020_en.gif)
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “Major Depressive Disorder – Pipeline Insight, 2021,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Major Depressive Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Major Depressive Disorder: Overview
Major Depressive Disorder (MDD), also referred as depression, is a serious medical illness that disrupts a person’s mood, behavior, thought processes, apart from degrading the physical health. It should not be mistaken for the passing feelings of unhappiness that everyone experiences, nor should it be confused with the intense grief brought about by the death of a loved one. Sadness and grief are normal reactions to life stresses. With time, and usually without medical treatment, sadness and grief lift, and people go on with their lives. By contrast, without specialized medical treatment, depression often persists. But with effective treatment, a large majority of people improve significantly. In most instances, MDD is a recurrent, episodic illness. Depression does not have a single cause. It can be triggered, or it may occur spontaneously without being associated with a life crisis, physical illness or other risk. Clinical suspicion is key to the diagnosis of MDD. Patients should be asked about depressed mood and/or lack of interest or pleasure when they present with nonspecific symptoms suggestive of depression. Clinicians should evaluate the patient for the following features: onset, duration, accompanying psychological symptoms, possible psychosocial precipitating factors (e.g., relationship problems, work-related stressors, or living conditions), and the effect of these symptoms on the patient’s daily life and function. Brain chemistry may contribute to an individual’s depression and may factor into their treatment. Antidepressants may produce some improvement within the first week or two of use yet full benefits may not be seen for two to three months.
'Major Depressive Disorder - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Major Depressive Disorder pipeline landscape is provided which includes the disease overview and Major Depressive Disorder treatment guidelines. The assessment part of the report embraces, in depth Major Depressive Disorder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Major Depressive Disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Major Depressive Disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Major Depressive Disorder Emerging Drugs
Further product details are provided in the repor
Major Depressive Disorder: Therapeutic Assessment
This segment of the report provides insights about the different Major Depressive Disorder drugs segregated based on following parameters that define the scope of the report, such as:
Major Depressive Disorder: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Major Depressive Disorder therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Major Depressive Disorder drugs.
Major Depressive Disorder Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Major Depressive Disorder – Pipeline Insight, 2021,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Major Depressive Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Major Depressive Disorder: Overview
Major Depressive Disorder (MDD), also referred as depression, is a serious medical illness that disrupts a person’s mood, behavior, thought processes, apart from degrading the physical health. It should not be mistaken for the passing feelings of unhappiness that everyone experiences, nor should it be confused with the intense grief brought about by the death of a loved one. Sadness and grief are normal reactions to life stresses. With time, and usually without medical treatment, sadness and grief lift, and people go on with their lives. By contrast, without specialized medical treatment, depression often persists. But with effective treatment, a large majority of people improve significantly. In most instances, MDD is a recurrent, episodic illness. Depression does not have a single cause. It can be triggered, or it may occur spontaneously without being associated with a life crisis, physical illness or other risk. Clinical suspicion is key to the diagnosis of MDD. Patients should be asked about depressed mood and/or lack of interest or pleasure when they present with nonspecific symptoms suggestive of depression. Clinicians should evaluate the patient for the following features: onset, duration, accompanying psychological symptoms, possible psychosocial precipitating factors (e.g., relationship problems, work-related stressors, or living conditions), and the effect of these symptoms on the patient’s daily life and function. Brain chemistry may contribute to an individual’s depression and may factor into their treatment. Antidepressants may produce some improvement within the first week or two of use yet full benefits may not be seen for two to three months.
'Major Depressive Disorder - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Major Depressive Disorder pipeline landscape is provided which includes the disease overview and Major Depressive Disorder treatment guidelines. The assessment part of the report embraces, in depth Major Depressive Disorder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Major Depressive Disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Major Depressive Disorder R&D. The therapies under development are focused on novel approaches to treat/improve Major Depressive Disorder.
This segment of the Major Depressive Disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Major Depressive Disorder Emerging Drugs
- AXS-05: Axsome Therapeutics
- Cariprazine: Allergan
- SAGE-217: SAGE therapeutics
- Seltorexant: Janssen Research & Development
- Brexpiprazole: Otsuka Pharmaceutical
- PRAX 114: Praxis Precision Medicines
- SEP 4199: Sunovion Pharmaceuticals
Further product details are provided in the repor
Major Depressive Disorder: Therapeutic Assessment
This segment of the report provides insights about the different Major Depressive Disorder drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Major Depressive Disorder
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Major Depressive Disorder: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Major Depressive Disorder therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Major Depressive Disorder drugs.
Major Depressive Disorder Report Insights
- Major Depressive Disorder Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Major Depressive Disorder drugs?
- How many Major Depressive Disorder drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Major Depressive Disorder?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Major Depressive Disorder therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Major Depressive Disorder and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Major Depressive Disorder: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Major Depressive Disorder – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Major Depressive Disorder companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Major Depressive Disorder Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Preregistration)
Comparative Analysis
AXS-05: Axsome Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
SEP 4199: Sunovion Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I/II)
Comparative Analysis
SPL026: Small Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Major Depressive Disorder Key Companies
Major Depressive Disorder Key Products
Major Depressive Disorder- Unmet Needs
Major Depressive Disorder- Market Drivers and Barriers
Major Depressive Disorder- Future Perspectives and Conclusion
Major Depressive Disorder Analyst Views
Major Depressive Disorder Key Companies
Appendix
Executive Summary
Major Depressive Disorder: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Major Depressive Disorder – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Major Depressive Disorder companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Major Depressive Disorder Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Preregistration)
Comparative Analysis
AXS-05: Axsome Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
SEP 4199: Sunovion Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I/II)
Comparative Analysis
SPL026: Small Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Major Depressive Disorder Key Companies
Major Depressive Disorder Key Products
Major Depressive Disorder- Unmet Needs
Major Depressive Disorder- Market Drivers and Barriers
Major Depressive Disorder- Future Perspectives and Conclusion
Major Depressive Disorder Analyst Views
Major Depressive Disorder Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Major Depressive Disorder
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Major Depressive Disorder
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Major Depressive Disorder
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Major Depressive Disorder
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products